OvaScience Reports First Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Leerink Partners Remains Sidelined on OvaScience (OVAS) Following 1Q
May 6, 2016 8:45 AM EDTLeerink Partners reiterated a Market Perform rating on OvaScience (NASDAQ: OVAS), and raised the price target to $7.00 (from $6.00), following the company's 1Q earnings report. OVAS reported EPS of ($0.80) which was below Leerink Partners' estimate of ($0.75). The weakness in EPS was due to higher than expected COGS and R&D... More
OvaScience (OVAS) Misses Q1 EPS by 8c
May 5, 2016 4:01 PM EDTOvaScience (NASDAQ: OVAS) reported Q1 EPS of ($0.80), $0.08 worse than the analyst estimate of ($0.72). Revenue for the quarter came in at $146 thousand versus the consensus estimate of $110 thousand.
"OvaScience is currently focused on building our operational platform to support the expansion of the AUGMENT... More
